Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration
Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxid...
Gespeichert in:
Veröffentlicht in: | Neuroscience letters 2008-03, Vol.434 (1), p.139-143 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 143 |
---|---|
container_issue | 1 |
container_start_page | 139 |
container_title | Neuroscience letters |
container_volume | 434 |
creator | Di-Pietro, Priscila B. Dias, Márcia L. Scaini, Giselli Burigo, Márcio Constantino, Larissa Machado, Roberta A. Dal-Pizzol, Felipe Streck, Emilio L. |
description | Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (
N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12
h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12
h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy. |
doi_str_mv | 10.1016/j.neulet.2008.01.051 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70409670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304394008001213</els_id><sourcerecordid>70409670</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhHyDkC9wSxok3Ti5IqOKjUgUXOFtje6J6SZxiO1Vz5o_jZVdw4zSW55nX9mPGXgqoBYju7aEOtE6U6wagr0HUsBeP2E70qqnUoJrHbActyKodJFywZykdAAqyl0_ZhehLR7Vyx35dh1tvfPZL4MvITUQfuI2E2QfiP3zARBxt9vc-bxzHTJFHCjhxn-wtzR7LgmPOFFbM5LjZ-JcKLeVtslvKdIzB4LijkeLygPOfDVeKTzni8eDn7MmIU6IX53rJvn_88O3qc3Xz9dP11fubyrYD5ErKrhtdQyh6cCMYQT1I13cKULVW7DuD0kDXCzXI0dHQKOFURwOUjjHUtpfszSn3Li4_V0pZz-URNE0YaFmTViBhKHEFlCfQxiWlSKO-i37GuGkB-ihfH_RJvj7K1yB0MVvGXp3zVzOT-zd0tl2A12cAk8VpjBisT3-5Bsrn7TtVuHcnjoqNe09RJ-spWHI-ks3aLf7_N_kNqzqnZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70409670</pqid></control><display><type>article</type><title>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Di-Pietro, Priscila B. ; Dias, Márcia L. ; Scaini, Giselli ; Burigo, Márcio ; Constantino, Larissa ; Machado, Roberta A. ; Dal-Pizzol, Felipe ; Streck, Emilio L.</creator><creatorcontrib>Di-Pietro, Priscila B. ; Dias, Márcia L. ; Scaini, Giselli ; Burigo, Márcio ; Constantino, Larissa ; Machado, Roberta A. ; Dal-Pizzol, Felipe ; Streck, Emilio L.</creatorcontrib><description>Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (
N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12
h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12
h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.</description><identifier>ISSN: 0304-3940</identifier><identifier>EISSN: 1872-7972</identifier><identifier>DOI: 10.1016/j.neulet.2008.01.051</identifier><identifier>PMID: 18304734</identifier><identifier>CODEN: NELED5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Acetylcysteine - pharmacology ; Acetylcysteine - therapeutic use ; Animals ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Biological and medical sciences ; Brain - drug effects ; Brain - enzymology ; Brain - physiopathology ; Brain Diseases, Metabolic - drug therapy ; Brain Diseases, Metabolic - enzymology ; Brain Diseases, Metabolic - physiopathology ; Creatine kinase ; Creatine Kinase - antagonists & inhibitors ; Creatine Kinase - metabolism ; Deferoxamine ; Deferoxamine - pharmacology ; Deferoxamine - therapeutic use ; Down-Regulation - drug effects ; Down-Regulation - physiology ; Fundamental and applied biological sciences. Psychology ; Ischemia - complications ; Kidney Diseases - complications ; Male ; N-Acetylcysteine ; Nerve Degeneration - drug therapy ; Nerve Degeneration - enzymology ; Nerve Degeneration - physiopathology ; Oxidative Stress - drug effects ; Oxidative Stress - physiology ; Rats ; Rats, Wistar ; Renal failure ; Subcellular Fractions ; Time Factors ; Treatment Outcome ; Uremia - drug therapy ; Uremia - enzymology ; Uremia - physiopathology ; Vertebrates: nervous system and sense organs</subject><ispartof>Neuroscience letters, 2008-03, Vol.434 (1), p.139-143</ispartof><rights>2008 Elsevier Ireland Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</citedby><cites>FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304394008001213$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20187567$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18304734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di-Pietro, Priscila B.</creatorcontrib><creatorcontrib>Dias, Márcia L.</creatorcontrib><creatorcontrib>Scaini, Giselli</creatorcontrib><creatorcontrib>Burigo, Márcio</creatorcontrib><creatorcontrib>Constantino, Larissa</creatorcontrib><creatorcontrib>Machado, Roberta A.</creatorcontrib><creatorcontrib>Dal-Pizzol, Felipe</creatorcontrib><creatorcontrib>Streck, Emilio L.</creatorcontrib><title>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</title><title>Neuroscience letters</title><addtitle>Neurosci Lett</addtitle><description>Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (
N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12
h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12
h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.</description><subject>Acetylcysteine - pharmacology</subject><subject>Acetylcysteine - therapeutic use</subject><subject>Animals</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - enzymology</subject><subject>Brain - physiopathology</subject><subject>Brain Diseases, Metabolic - drug therapy</subject><subject>Brain Diseases, Metabolic - enzymology</subject><subject>Brain Diseases, Metabolic - physiopathology</subject><subject>Creatine kinase</subject><subject>Creatine Kinase - antagonists & inhibitors</subject><subject>Creatine Kinase - metabolism</subject><subject>Deferoxamine</subject><subject>Deferoxamine - pharmacology</subject><subject>Deferoxamine - therapeutic use</subject><subject>Down-Regulation - drug effects</subject><subject>Down-Regulation - physiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Ischemia - complications</subject><subject>Kidney Diseases - complications</subject><subject>Male</subject><subject>N-Acetylcysteine</subject><subject>Nerve Degeneration - drug therapy</subject><subject>Nerve Degeneration - enzymology</subject><subject>Nerve Degeneration - physiopathology</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidative Stress - physiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Renal failure</subject><subject>Subcellular Fractions</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Uremia - drug therapy</subject><subject>Uremia - enzymology</subject><subject>Uremia - physiopathology</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0304-3940</issn><issn>1872-7972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EokvhHyDkC9wSxok3Ti5IqOKjUgUXOFtje6J6SZxiO1Vz5o_jZVdw4zSW55nX9mPGXgqoBYju7aEOtE6U6wagr0HUsBeP2E70qqnUoJrHbActyKodJFywZykdAAqyl0_ZhehLR7Vyx35dh1tvfPZL4MvITUQfuI2E2QfiP3zARBxt9vc-bxzHTJFHCjhxn-wtzR7LgmPOFFbM5LjZ-JcKLeVtslvKdIzB4LijkeLygPOfDVeKTzni8eDn7MmIU6IX53rJvn_88O3qc3Xz9dP11fubyrYD5ErKrhtdQyh6cCMYQT1I13cKULVW7DuD0kDXCzXI0dHQKOFURwOUjjHUtpfszSn3Li4_V0pZz-URNE0YaFmTViBhKHEFlCfQxiWlSKO-i37GuGkB-ihfH_RJvj7K1yB0MVvGXp3zVzOT-zd0tl2A12cAk8VpjBisT3-5Bsrn7TtVuHcnjoqNe09RJ-spWHI-ks3aLf7_N_kNqzqnZA</recordid><startdate>20080321</startdate><enddate>20080321</enddate><creator>Di-Pietro, Priscila B.</creator><creator>Dias, Márcia L.</creator><creator>Scaini, Giselli</creator><creator>Burigo, Márcio</creator><creator>Constantino, Larissa</creator><creator>Machado, Roberta A.</creator><creator>Dal-Pizzol, Felipe</creator><creator>Streck, Emilio L.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080321</creationdate><title>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</title><author>Di-Pietro, Priscila B. ; Dias, Márcia L. ; Scaini, Giselli ; Burigo, Márcio ; Constantino, Larissa ; Machado, Roberta A. ; Dal-Pizzol, Felipe ; Streck, Emilio L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-4466fd2ea180df0b1e804d8670a73c156ba4b0681794fde9271d76e9056bbbe33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acetylcysteine - pharmacology</topic><topic>Acetylcysteine - therapeutic use</topic><topic>Animals</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - enzymology</topic><topic>Brain - physiopathology</topic><topic>Brain Diseases, Metabolic - drug therapy</topic><topic>Brain Diseases, Metabolic - enzymology</topic><topic>Brain Diseases, Metabolic - physiopathology</topic><topic>Creatine kinase</topic><topic>Creatine Kinase - antagonists & inhibitors</topic><topic>Creatine Kinase - metabolism</topic><topic>Deferoxamine</topic><topic>Deferoxamine - pharmacology</topic><topic>Deferoxamine - therapeutic use</topic><topic>Down-Regulation - drug effects</topic><topic>Down-Regulation - physiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Ischemia - complications</topic><topic>Kidney Diseases - complications</topic><topic>Male</topic><topic>N-Acetylcysteine</topic><topic>Nerve Degeneration - drug therapy</topic><topic>Nerve Degeneration - enzymology</topic><topic>Nerve Degeneration - physiopathology</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidative Stress - physiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Renal failure</topic><topic>Subcellular Fractions</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Uremia - drug therapy</topic><topic>Uremia - enzymology</topic><topic>Uremia - physiopathology</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di-Pietro, Priscila B.</creatorcontrib><creatorcontrib>Dias, Márcia L.</creatorcontrib><creatorcontrib>Scaini, Giselli</creatorcontrib><creatorcontrib>Burigo, Márcio</creatorcontrib><creatorcontrib>Constantino, Larissa</creatorcontrib><creatorcontrib>Machado, Roberta A.</creatorcontrib><creatorcontrib>Dal-Pizzol, Felipe</creatorcontrib><creatorcontrib>Streck, Emilio L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di-Pietro, Priscila B.</au><au>Dias, Márcia L.</au><au>Scaini, Giselli</au><au>Burigo, Márcio</au><au>Constantino, Larissa</au><au>Machado, Roberta A.</au><au>Dal-Pizzol, Felipe</au><au>Streck, Emilio L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration</atitle><jtitle>Neuroscience letters</jtitle><addtitle>Neurosci Lett</addtitle><date>2008-03-21</date><risdate>2008</risdate><volume>434</volume><issue>1</issue><spage>139</spage><epage>143</epage><pages>139-143</pages><issn>0304-3940</issn><eissn>1872-7972</eissn><coden>NELED5</coden><abstract>Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (
N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12
h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12
h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>18304734</pmid><doi>10.1016/j.neulet.2008.01.051</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0304-3940 |
ispartof | Neuroscience letters, 2008-03, Vol.434 (1), p.139-143 |
issn | 0304-3940 1872-7972 |
language | eng |
recordid | cdi_proquest_miscellaneous_70409670 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Acetylcysteine - pharmacology Acetylcysteine - therapeutic use Animals Antioxidants - pharmacology Antioxidants - therapeutic use Biological and medical sciences Brain - drug effects Brain - enzymology Brain - physiopathology Brain Diseases, Metabolic - drug therapy Brain Diseases, Metabolic - enzymology Brain Diseases, Metabolic - physiopathology Creatine kinase Creatine Kinase - antagonists & inhibitors Creatine Kinase - metabolism Deferoxamine Deferoxamine - pharmacology Deferoxamine - therapeutic use Down-Regulation - drug effects Down-Regulation - physiology Fundamental and applied biological sciences. Psychology Ischemia - complications Kidney Diseases - complications Male N-Acetylcysteine Nerve Degeneration - drug therapy Nerve Degeneration - enzymology Nerve Degeneration - physiopathology Oxidative Stress - drug effects Oxidative Stress - physiology Rats Rats, Wistar Renal failure Subcellular Fractions Time Factors Treatment Outcome Uremia - drug therapy Uremia - enzymology Uremia - physiopathology Vertebrates: nervous system and sense organs |
title | Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T15%3A56%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20brain%20creatine%20kinase%20activity%20after%20renal%20ischemia%20is%20attenuated%20by%20N-acetylcysteine%20and%20deferoxamine%20administration&rft.jtitle=Neuroscience%20letters&rft.au=Di-Pietro,%20Priscila%20B.&rft.date=2008-03-21&rft.volume=434&rft.issue=1&rft.spage=139&rft.epage=143&rft.pages=139-143&rft.issn=0304-3940&rft.eissn=1872-7972&rft.coden=NELED5&rft_id=info:doi/10.1016/j.neulet.2008.01.051&rft_dat=%3Cproquest_cross%3E70409670%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70409670&rft_id=info:pmid/18304734&rft_els_id=S0304394008001213&rfr_iscdi=true |